TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Akihito KawazoeKota ItahashiNoboru YamamotoDaisuke KotaniYasutoshi KubokiHiroya TaniguchiKenichi HaranoYoichi NaitoMitsuko SuzukiMiki FukutaniTsukiko HiguchiTakashi IkenoMasashi WakabayashiAkihiro SatoShohei KoyamaHiroyoshi NishikawaKohei ShitaraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
TAS-116 160 mg plus nivolumab had manageable safety profiles and antitumor activity, especially for MSS colorectal cancer patients.